Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

National News

New AIDS Drug Price Spurs Some Questions

March 13, 2003

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

The Food and Drug Administration is to decide by Sunday whether to approve Roche's new drug Fuzeon, used to treat drug-resistant HIV, for the US market. AIDS activists applaud Fuzeon's development, but said it will not do much good if patients cannot afford its high price -- recently announced at $20,409 a year in Europe. Roche cannot release the US price until Fuzeon is approved, but said it would be close to the European price.

Medicaid pays for about 50 percent of all AIDS drugs, but it is under intense pressure as states struggle with budget deficits. Government-funded AIDS Drug Assistance Programs cover about 30 percent of medications, and budget problems have already forced 16 of the 56 ADAPs to cut back on services. "We don't think we can add Fuzeon without cutting something else," said Michael Montgomery, who oversees California's ADAP.

Roche Chair and CEO Franz Hummer said the drug's price reflects the $600 million cost of development, as well as the cost of manufacturing and research for other AIDS medicines. Fuzeon's manufacture is very complicated, requiring three times the normal number of ingredients and four times the average number of processing steps. Initially, only 12,000 to 15,000 patients worldwide will have access to Fuzeon due to production constraints.

Most in the AIDS community agree demand for Fuzeon will outstrip supply even with the high price. Some analysts and activists insist Roche is taking advantage of its monopoly before other new treatments come onto the market. Others point out that Roche has to share profits with Trimeris, the company that discovered Fuzeon, on US and Canadian sales. Roche could turn a profit on Fuzeon in three years. The industry average for a new drug is 16 years, with blockbusters making money in 5-10 years.

Advertisement
Profits would also be affected by such factors as discounts to Medicaid, which are required by law, and price cuts for ADAPs, which are the norm. Roche has also promised to give some drug away free.

Back to other CDC news for March 13, 2003

Previous Updates

Adapted from:
Associated Press
03.13.03; Theresa Agovino

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More on HIV Medications
More on Fuzeon (Enfuvirtide, T-20)
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

Tools
 

Advertisement